# US 2019/0314315 A1 · Methods of Treating Neurodevelopmental Diseases and Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314315 A1
- Document ID: US20190314315A1
- Status: Published application
- Kind: A1
- Application number: 16/282,880
- Filed: 2019-02-22
- Published: 2019-10-17
- Earliest claimed: 2014-06-06
- Assignees: Deakin University; The Florey Institute of Neuroscience and Mental Health
- Applicants: Deakin University; The Florey Institute of Neuroscience and Mental Health
- Inventors: Steve CHEUNG; Wah Chin BOON
- Web page: https://patentgrep.com/patent/US20190314315A1

## CPC

- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 35/644: Beeswax; Propolis; Royal jelly; Honey
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.

## Claims

### Claim 1

A method for the treatment and/or prophylaxis of a disease or disorder of the central nervous system, comprising administering to a mammal in need thereof an effective amount of trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof, wherein the trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof is administered in a dosage in the range of 0.01 to 6000 mg/day.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease or disorder is a neurodevelopmental disease or disorder.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the disease or disorder is an acquired neurodevelopmental disease or disorder, a congenital neurodevelopmental disease or disorder, or a related condition.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the disease or disorder is an autism spectrum disorder.

### Claim 5 (depends on 4)

The method according to claim 4 wherein the autism spectrum disorder is selected from the group consisting of Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder and Pervasive Developmental Disorder-Not Otherwise Specified, and Rett syndrome.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof is administered as a composition.

### Claim 7 (depends on 6)

The method according to claim 6 wherein the composition comprises royal jelly, an extract of royal jelly, or a composition derived from royal jelly.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof is administered in a dosage in the range of 100 to 2000 mg/day.

### Claim at position 9

-19. (canceled)

### Claim 20

A composition comprising trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof for the treatment and/or prophylaxis of a neurodevelopmental disease or disorder, wherein the trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof is administered in a dosage in the range of 0.01 to 6000 mg/day.

### Claim 21 (depends on 20)

A composition according to claim 20 wherein the disease or disorder is selected from the group consisting of Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder and Pervasive Developmental Disorder-Not Otherwise Specified, and Rett syndrome.

### Claim 22

A therapeutic agent for use in the treatment and/or prophylaxis of a neurodevelopmental disease or disorder, wherein the agent is trans 10-hydroxy-2-decenoic acid or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

A therapeutic agent for use according to claim 22 wherein the disease or disorder is selected from the group consisting of Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder and Pervasive Developmental Disorder-Not Otherwise Specified, and Rett syndrome.
